BioStock: Annual report highlights Immunicum’s competitive advantages

Last week, Immunicum released their annual report summarizing their activities during 2019. In addition to the milestones reached through their work with ilixadencel, the clear and in-depth report sheds light on the company’s immuno-oncology development strategy and why it, along with other factors, gives them a competitive edge. BioStock takes a closer look.

Read the full article at biostock.se:

https://www.biostock.se/en/annual-report-highlights-immunicums-competitive-advantages/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se